Astellas has been taken to task for breaching the UK pharma industry's self-regulatory Code of Practice during an event convened to discuss its prostate cancer therapy Xtandi in Italy last... Read more
More patients with the life-limiting disease cystic fibrosis are to receive new treatment Kalydeco, after NHS England agreed to fund the drug.But charity the Cystic Fibrosis Trust has hit out... Read more
Latest Press Releases from the Global Pharma Showcase
The World's Largest Healthcare Event - tHIS Opens to Record Breaking Crowds
SHANGHAI, May 19, 2015 -- The 2015 Health Industry Summit (tHIS), an event that was predicted to transform the Chinese healthcare industry sector, opened to huge crowds on May 15, with over 210,000 visitors from 150 countries in attendance.
Held at the brand new National Convention & Exhibition Center in Shanghai, tHIS is a large-scale healthcare event that combines China's three top medical equipment and pharmaceutical exhibitions CMEF, PHARMCHINA and API China into one mega healthcare event, in doing so completing the entire value chain for the health industry.
The 2015 exhibition occupied a total area of 290,000 sqm of exhibition space and showcases the latest cutting edge medical equipment and equipment manufacturing solutions, pharmaceutical formulations and ingredients, manufacturing technologies, natural health and nutrition products from over 6,800 exhibitors.
Well-known healthcare equipment giants like GE, SIEMENS, Philips, Mindray, and United Imaging had specially designed stands that served as a backdrop for the launch of the hundreds of new to market products, with GE Healthcare unveiling its Revolution TC imaging series, Mindray, with its flexible POC ultrasound system 'mobiEye 700', and ContextVision with GOPICE 2.0 software for imaging among a flurry of launch activities. Global Senior Vice President of GE/ President and CEO of GE China Ms. Rachel Duan shares her views on the event's success: "Medical & healthcare equipment manufacturers highly values this platform, all bringing with them the latest and best technology to showcase. All the leading companies in the industry are here, all of the top industry talents are here, there lies the explosive popularity of the event."
Meanwhile, anticipating a huge turnout and with a focus on APIs and formulations, China's top pharmaceutical manufacturers and distributors were ready to welcome tens of thousands of domestic and international buyers, while fast-growing market segments such as natural health and nutritional products represented by Natural Health and Nutrition China have seen participation double in size, and the medical device manufacturing show ICMD has seen unprecedented 300% growth in exhibitor participation.
Organizer Reed Sinopharm, a joint venture between the world's leading event organizer Reed Exhibitions and China's leading state-owned pharmaceutical group Sinopharm, used their combined strength of international networks and industry connectivity to write a new chapter for China's healthcare industry, as it transforms from localized industry developments into a maturing market with global reach.
According to a state-issued strategic whitepaper in 2013, China expects the total market size of its health sector to triple to a massive USD 1.2 trillion by 2020. This growth potential in China is partly attributable to its growing ageing population, expected to account for more than 30% of the total by 2050. This coupled with increasing urbanization and the further loosening of the one-child policy will ensure a boom in the birth rate, putting the current health system and hospital facilities under strain.
Furthermore, the new top level investment forum - Healthcare China heads a grand list of 107 conferences which completes the expo and conference mix, covering all the key fields and industry topics, with major conferences including the China Integrated Medical Imaging Summit, Asian Nuclear Medicine Academic Forum and Sino-Europe Pharmaceutical Forum.
Reed Sinopharm commented that tHIS will be held annually in Shanghai every spring and the event is anticipated to become the key platform to define the future trends of the healthcare sector in China and the world.
James Wang, +86-139-1022-8182, firstname.lastname@example.org
Claire Bowie joins pharmaphorum as Editorial Director
pharmaphorum media is delighted to announce the appointment of Claire Bowie to the newly created position of Editorial Director, effective immediately.
Claire joins from PharmaTimes Media Ltd where she started as editor in 2000 before becoming managing editor and, most recently, managing director.
With a background in the sciences, Claire helped establish and develop the editorial direction and success of the magazine and online news services for the biopharmaceutical and healthcare industries. This experience will now be applied to further developing the presence of the digital publication pharmaphorum.com and the associated services.
“Being editor and then managing editor of PharmaTimes for almost 15 years and being given the opportunity to work with an outstanding team to build and develop a publication with clarity of voice and independence of view - in a world where the commercial pressures of publishing are all too evident – was a real privilege,” Claire comments. “This is an ethos I hope to bring to my new role at pharmaphorum media.”
“The addition of Claire to our growing pharmaphorum media team further strengthens our capabilities and demonstrates the value we place on investing in and developing our people,” adds Paul Tunnah, founder and CEO. “Claire’s experience and expertise in the delivery of quality content will significantly benefit our offering to pharmaceutical industry clients and broader healthcare partners.”
SIMPONI® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Nr-Axial SpA
View full release
New Data on Quality-of-Life Benefits of SIMPONI® (Golimumab) in Treating Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axial SpA)
SIMPONI® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Nr-Axial SpA
Hoddesdon, UK, 10 June, 2015 – Merck Sharp & Dohme (MSD), known as Merck in the United States and Canada, today announced additional data from a subanalysis1 of the multicentre, randomised, double-blind, placebo-controlled GO-AHEAD study on the effect of SIMPONI® (golimumab) in treating patients with non-radiographic axial spondyloarthritis (nr-axial SpA).2
Quality of Life (QoL)1 findings from the GO-AHEAD study, published at EULAR Congress this week, showed that patients with nr-axial SpA treated with SIMPONI® had greater improvements than those treated with placebo. At week 16, SIMPONI® patients had greater improvements from baseline QoL than those receiving placebo against all scales of the Ankylosing Spondylitis Quality of Life (ASQoL), EuroQoL 5-Dimension (EQ-5D), and the 36-item Short Form Health Survey (SF-36).1 Patients treated with SIMPONI® also experienced greater percentage improvements in measures of overall work impairment at week 16 versus placebo-treated patients (-21.1 vs -11.7, respectively; P=0.0391), as well as in activity impairment at week 16 (-24.9 vs -8.6, respectively; P<0.0001) as evaluated by the Work Productivity and Activity Impairment (WPAI) questionnaire.1
Axial spondyloarthritis (axial SpA), which encompasses both nr-axial SpA and ankylosing spondylitis (AS),3 is a painful and potentially progressive condition that mainly affects the spine and pelvic joints, commonly characterised by chronic lower back pain and stiffness.4
“The burden of disease is similar in axial SpA and AS, and effective suppression of inflammation can result in a considerable improvement of quality of life outcome parameters”, explains study author Professor Joachim Sieper, consultant and head rheumatologist at the Charité University Hospital, Berlin. “Such a good effect on disease activity and quality of life was nicely shown in the current study of the TNF-blocker golimumab in nr-axial SpA patients compared to the group of patients treated with placebo.”
The key results of the GO-AHEAD study, also presented at the EULAR 2015 Congress2 and previously presented at the American College of Rheumatology (ACR) Congress, November 2014,5 demonstrated the efficacy of SIMPONI® in patients with nr-axial SpA.2 The primary-endpoint data showed that 71.1 per cent of patients treated with SIMPONI® achieved ASAS 20, at 16 weeks compared with 40 per cent of placebo-treated patients (P<0.0001).2 The ASAS (ASsessments in Ankylosing Spondylitis) assess symptomatic outcomes across domains including physical function, pain, global disease assessment, spinal stiffness and inflammation.
Adverse events occurred in 41 per cent and 47 per cent of patients treated with SIMPONI® and placebo, respectively. Serious adverse events occurred in one SIMPONI® patient (female partner-reported foetal death) and two placebo patients (presence of gallstones and back pain). There were no events of serious infections, serious opportunistic infections, active tuberculosis, malignancies, serious systemic hypersensitivity, or deaths during the placebo-controlled part of the study up to week 16.2
In May 2015, SIMPONI® received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of nr-axial SpA.6 If approved by the European Commission, the new indication will mean that SIMPONI® will be available as a once-monthly treatment option for adult patients with severe, active nr-axial SpA with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs). Subsequent to the CHMP opinion, the EU Commission Decision will mark the implementation of this addition to the existing approved indications in rheumatology: AS, psoriatic arthritis (PsA) and rheumatoid arthritis (RA). SIMPONI® is also approved for the treatment of ulcerative colitis (UC).7
NICE and spondyloarthritis
In the UK, NICE (National Institute for Health and Care Excellence) is reviewing the guidelines for the diagnosis and management of spondyloarthritic conditions, including nr-axial SpA.8 Additionally, a NICE Multiple Technology Appraisal (MTA) is in progress evaluating the use of adalimumab, certolizumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and nr-axial SpA, with publication anticipated in September 2015.9
MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.
For further information please contact:
F Suleyman (MSD)
+44 (0)1992 455389
Rebecca Aris (Pegasus)
+44 (0)1903 712034
Notes to Editors
GO-AHEAD was a Phase 3b double-blind, randomised, placebo-controlled trial conducted in patients 18 to 45 years of age with active nr-axial SpA, diagnosed according to the ASsessment in Ankylosing Spondylitis (ASAS) criteria.2
The study evaluated 197 patients who were treated with either golimumab 50 mg (n=97) or placebo (n=100) subcutaneous injections every four weeks. The mean patient age was 31 years and more than half of the patients were male (57 percent). The primary endpoint of the study was the percentage of patients who attained ASAS20 at week 16. Key secondary endpoints included percentage of patients attaining ASAS40, ASAS partial remission, Bath AS Disease Activity Index (BASDAI) 50; and change from baseline in sacroiliac joint inflammation on MRI (SPondyloArthritis Research Consortium of Canada [SPARCC] score).2
The study also assessed a subgroup of patients who showed objective signs of inflammation (OSI) by MRI and/or elevated C-reactive protein (CRP) at baseline. This subset of patients comprised approximately 80 per cent of the total population.2
Adverse events occurred in 41 per cent and 47 per cent of patients treated with golimumab and placebo, respectively. Serious adverse events occurred in one golimumab patient (female partner of patient-reported foetal death) and two placebo patients (presence of gallstones and back pain). There were no events of serious infections, serious opportunistic infections, active tuberculosis, malignancies, serious systemic hypersensitivity, or deaths during the placebo-controlled part of the study up to week 16.2
About Axial Spondyloarthritis
Axial spondyloarthritis is a painful and potentially progressive form of inflammatory arthritis that mainly affects the spine and pelvic joints and most commonly results in chronic lower back pain.4 It typically begins in the late teens and early twenties and in severe cases can result in complete fusion of the spinal vertebrae and cause structural damage to hips and other joints.4 The term axial spondyloarthritis covers both non-radiographic axial spondyloarthritis and ankylosing spondylitis. In patients with non-radiographic axial spondyloarthritis, patients experience symptoms but damage to the joints is not yet visible on X-ray.3 A proportion of these patients will move on to ankylosing spondylitis with typical radiographic changes.10 Often misdiagnosed as "just back pain" in the early stages,11 axial spondyloarthritis is a systemic inflammatory disease that, in addition to its effect on the spine, can affect other areas such as peripheral joints, eyes, and the bowel.4
About SIMPONI® (golimumab)
Golimumab is a human monoclonal antibody that targets and neutralises tumour necrosis factor (TNF)-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation and damage to bones, cartilage and tissue. Licensed indications for golimumab include: moderate to severe, active rheumatoid arthritis in adults, in combination with methotrexate, when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate; severe, active and progressive rheumatoid arthritis, in combination with methotrexate, in adults not previously treated with methotrexate; active and progressive psoriatic arthritis in adult patients, alone or in combination with methotrexate, when the response to previous DMARD therapy has been inadequate; and severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Golimumab is also the first and only four-weekly, subcutaneous biologic therapy approved for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.Golimumabis available either through the SmartJect autoinjector/prefilled pen or a prefilled syringe as a SC administered injection.
Simponi is a Registered Trademark owned by Johnson & Johnson and licensed to Merck and Co., Inc. (known as MSD outside the US), Whitehouse Station, New Jersey, USA.
Please refer to the Summary of Product Characteristics for full information on ‘Simponi’ including contraindications, precautions, special warnings and side effects. Available from: www.medicines.org.uk/EMC/medicine/23766/SPC/Simponi+50+mg+solution+for+injection.
At MSD we believe the most important thing we make is a difference. We operate in more than 140 countries and through our prescription medicines, vaccines, biologic therapies, and animal health products we work with customers to bring innovative healthcare solutions to those who need them the most. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information visit www.msd-uk.com. The company is known as Merck in the United States and Canada. Everywhere else, we are known as MSD.
Maksymowych WP et al. Quality of life in patients with active nonradiographic axial spondyloarthritis after 16 weeks of golimumab treatment. Abstract 3046. The 16th EULAR Annual European Congress of Rheumatology 2015, Rome, 10-13 June, 2015. Accessed June 2015.
Sieper J et al. A randomized, double-blind, placebo-controlled, 16-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Abstract 2114. The 16th EULAR Annual European Congress of Rheumatology 2015, Rome, 10-13 June, 2015. Accessed June 2015.
National Anklyosing Spondylitis society website. Available at: nass.co.uk. Accessed May 2015.
American College of Rheumatology (ACR). Spondylarthritis (Spondylarthropathy) website. Available at: www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Spondylarthritis_(Spondylarthropathy). Accessed April 2015.
Sieper J et al. A randomized, double-blind, placebo-controlled, 16-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Abstract 2938. American College of Rheumatology, Boston, 15-19 November, 2014. Accessed May 2015.
Patient Advocacy Groups Say Relationships with Pharmaceutical Companies Must Evolve to Keep Pace with Significant Changes in Healthcare Industry
WASHINGTON, D.C. – June 1, 2015– As patients and caregivers are confronted with a dramatically changing healthcare landscape, American patient advocacy organizations are evolving the work they do for these communities. The advocacy groups would like to see their relationships with pharmaceutical companies also change to keep pace, according to a report released today by the inVentiv Health Public Relations Group.
The report, “The New Partnership Paradigm: What Patient Advocates Seek from Pharmaceutical Partners,” is based on more than two months of interviews with nearly four dozen patient advocacy organizations representing patients with a variety of diseases and conditions, including cancer, mental health, and rare diseases. It highlights areas in which the patient advocates would like to see change in their relationships with pharmaceutical partners.
“Our research looked at how the external changes in healthcare, such as the Affordable Care Act, have affected the long-standing relationships between pharma and advocacy groups,” said Heather Gartman, Managing Director of inVentiv Health PR Group’s Washington, D.C. office, who helped lead the research. “Those changes are likely to have significant impact on how both sides regard the benefits of their relationship and work together in the future.”
The research revealed several core areas that form a patient advocate ‘wish list’ of changes intended to create greater mutual benefits and stronger relationships. The list of new best practices includes:
·Providing input earlier, not only in clinical trial design and execution but also in disease awareness and education campaigns;
·Strengthening and continuing to keep an open, ongoing dialogue regarding unmet needs, reporting, and information exchange;
·Creating additional patient registries that can be used for drug trial recruitment and outreach;
·Rewarding and respecting collaboration among patient groups; and
·Improving transparency and authenticity.
In the interviews, patient advocates said that these and other proposed changes detailed in the report will move what has largely been a transactional relationship with pharma companies to a more authentic partnership with industry.
For example, advocacy groups noted that changes in insurance plan benefits, including narrower physician networks, have impeded patient access to specialists. Individuals struggling with cancer or other grave illnesses often don’t understand how these changes will affect their care. The narrowing of networks is of concern to patients and pharmaceutical companies and is an issue on which they could partner to find solutions.
Several patient groups also acknowledged the need for greater collaboration and coordination among competing advocacy organizations. They suggested that pharma companies could encourage this trend – for example, by giving preference on funding decisions to organizations that collaborate.
“We undertook this research to assist our clients in both the pharmaceutical sector and the advocacy community in better understanding each side’s needs,” said Lisa Stockman, President of Public Relations and Medical Communications at inVentiv Health. “Such understanding leads to more effective partnerships and better support for patients facing new challenges in managing their healthcare and supporting research.”
The full report based on interviews with 43 organizations is available here. For additional information on the research or services inVentiv Health PR Group provides to patient advocacy organizations and pharmaceutical companies, contact Heather Gartman at email@example.com.
About inVentiv Health Public Relations Group inVentiv Health Public Relations Group is comprised of five global health communications agencies – Allidura Consumer, Biosector 2, Chamberlain Healthcare PR, Chandler Chicco Agency and Haas & Health Partner –that help launch brands and build the reputations of companies working to improve human health. With an integrated approach to communications, inVentiv Health PR Group agencies offer best-in-class capabilities spanning public relations, digital and social media, medical and scientific education, and analytics and measurement. Our teams create communications that drive corporate value, enhance brand perception, and deliver on the bottom line.
inVentiv Health PR Group is part of inVentiv Health and has offices in New York, Los Angeles, Washington, London, and Paris, and global healthcare network operations around the world. For more information, visit inVentivHealth.com/PR.
About inVentiv Health inVentiv Health is a global provider of best-in-class clinical development and comprehensive commercialization services, seamlessly linking the capabilities of a leading, global Clinical Research Organization (CRO) with a unique Contract Commercial Organization (CCO). inVentiv Health helps clients improve performance, reduce risk, and speed much-needed therapies to market. With 13,000 employees providing services to clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies developing and delivering medicines in a complex operating, regulatory, and reimbursement environment. Our clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team.
inVentiv Health brings business strategy to science and scientific expertise to business for the better treatment of patients worldwide. For more information, visit inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and terminations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our debt instruments and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.
Launch of the 2015 QuDoS in MS (recognising Quality in the Delivery of Services in Multiple Sclerosis) Awards programme
The inaugural QuDoS in MS Awards, established to recognise Quality in the Delivery of Services in Multiple Sclerosis, programme is now open for entry to teams and individuals working within the field of multiple sclerosis (MS).
Recently launched, the QuDoS in MS Awards highlight innovation and excellence in MS management and service delivery as well as the valuable contribution of those dedicated to improving the quality of life and experience of care for those with MS.
pharmaphorum media is delighted to be working in partnership with the Multiple Sclerosis Trust as part of the pharmaphorum healthcare partners brand on this programme. The programme comprises both an awards event and subsequent dissemination opportunities, and has the support and active participation of key industry stakeholders, including Biogen, Genzyme and Novartis.
Entries are invited from MS specialist nurses, other nurses working in MS, allied health professionals including physiotherapists and occupational therapists, commissioners in CCGs or NHS England, neurologists, pharmacists, GPs, and other healthcare professionals working in primary care, hospitals or the broader community.
The entry deadline is 5pm on Thursday 3rd September 2015 with judging taking place mid-October.
Amy Bowen, Director of Service Development, MS Trust said: “The Multiple Sclerosis Trust is pleased to be associated with the QuDoS in MS Awards – Recognising Quality in the Delivery of Services in Multiple Sclerosis – programme. This awards programme will enable teams and individuals across the UK to be recognised for their efforts in improving the quality of care for people living with multiple sclerosis.”
Sameena Conning, Associate Director, Public Affairs, Biogen Idec UK stated: “Biogen is proud to sponsor the QuDoS programme which aims to recognise innovation and celebrate good clinical practice in the disease management and support of patients with multiple sclerosis in UK. Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, haematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative haemophilia therapies. For additional information about the company, please visit www.biogen.com.”
Jitender Punn, MS Brand Manager, Novartis Pharmaceuticals Limited commented: “Novartis is delighted to support the QuDoS in MS Awards – Recognising Quality in the Delivery of Services in Multiple Sclerosis – programme. Novartis wants to discover, develop and successfully market innovative products to prevent and treat diseases, ease suffering and enhance the quality of life. Novartis is keen to support this programme because it recognises innovation and excellence in the treatment and care of patients with multiple sclerosis.”
Winners of the 2015 awards will be announced at a ceremony on Saturday November 7th, 2015 at the Beaumont Estate, Windsor, prior to the MS Trust Annual Conference, which takes place from 8-10 November 2015.